oncologyASCO: Immatics posts data on PRAME pipeline ahead of pivotal readoutImmatics has published a series of updates on its PRAME pipeline, using the American Society for Clinical Oncology (ASCO) Annual Meeting to share data on its lead candidate and next-generation progr … more ➔
Clinical trialOculis drops plans for diabetic macular edema drug after Phase III missSwiss ophthalmology biotech Oculis has suffered a major setback for its most advanced ophthalmology programme after two pivotal Phase III trials of OCS-01 eye drops in diabetic macular edema failed to … more ➔
M&AServier buys Edgewise muscular dystrophy business for up to US$2.65bnFrench pharmaceutical group Servier has agreed to acquire sevasemten and the muscular dystrophy business built around it from US biotech Edgewise Therapeutics Inc. in a transaction worth up to US$2.65bn, … more ➔
ROGER HARRIS/SCIENCE PHOTO LIBRA-stock.adobe.comM&AT-CURX buys Pantherna as the race for in vivo CAR-T gathers paceT-CURX acquires Pantherna: does this mark the start of a new race for the next generation of CAR-T therapies? The Würzburg- and Munich-based CAR-T company T-CURX is acquiring the Berlin-based mRNA and … more ➔
FinancingOSE Immunotherapeutics turns to IRIS for €19.3m bridge financingFrench immunotherapy developer OSE Immunotherapeutics has signed a term sheet for a flexible bridge equity financing with IRIS Capital Investment, giving the Nantes- and Paris-based biotech access to … more ➔
Nuclidium AGRadiopharmaceuticalsExtra boost for Nuclidium: financing round reaches €115 millionBasel-based Nuclidium AG has secured an additional tranche for its ongoing Series B financing round, bringing the total to approximately €115 million. The theranostics company is developing copper-based … more ➔
GSKGSK reports 19% functional cure rate for near-approval hepatitis B drugGSK has linked its chronic hepatitis B drug candidate to a 19% functional cure rate across a pair of Phase III trials, clearing the bar it set for clinical relevance. more ➔
clinical dataHansa data supports full approval plan for IdefirixSwedish rare immunology specialist Hansa Biopharma AB has reported positive topline results from a European post-authorisation efficacy study of Idefirix, strengthening its case to convert the kidney … more ➔
artificial intelligenceEx-Palantir execs raise $12M to develop AI operating system at PercepticPerceptic has raised a $12 million (€10.3 million) seed round to advance an AI operating system used by companies including CSL. more ➔
oncologyAdcendo inks MSD supply deal to run ADC-Keytruda combination studyAdcendo has struck a Keytruda supply agreement with MSD, positioning the Danish biotech to study an antibody-drug conjugate (ADC) with the blockbuster checkpoint inhibitor. more ➔
ROGER HARRIS/SCIENCE PHOTO LIBRA-stock.adobe.com
Nuclidium AG
